Elly V. Barry
Departments of Pediatric Oncology
Dana-Farber Cancer Institute
44 Binney St
Boston
USA
Name/email consistency: high
- Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Barry, E.V., Vrooman, L.M., Dahlberg, S.E., Neuberg, D.S., Asselin, B.L., Athale, U.H., Clavell, L.A., Larsen, E.C., Moghrabi, A., Samson, Y., Schorin, M.A., Cohen, H.J., Lipshultz, S.E., Sallan, S.E., Silverman, L.B. J. Clin. Oncol. (2008)
- Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. Barry, E., DeAngelo, D.J., Neuberg, D., Stevenson, K., Loh, M.L., Asselin, B.L., Barr, R.D., Clavell, L.A., Hurwitz, C.A., Moghrabi, A., Samson, Y., Schorin, M., Cohen, H.J., Sallan, S.E., Silverman, L.B. J. Clin. Oncol. (2007)
- Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Barry, E.V., Clark, J.J., Cools, J., Roesel, J., Gilliland, D.G. Blood (2007)